AMGEN Inc.

NASDAQ:AMGN   3:59:58 PM EDT
223.91
+1.37 (+0.62%)
4:30:53 PM EDT: $224.59 +0.68 (+0.30%)
Debt Financing / Related, Strategic Combinations

Amgen And Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement

Published: 01/06/2022 14:20 GMT
AMGEN Inc. (AMGN) - :amgen and Generate Biomedicines Announce Multi-target, Multi-modality Research Collaboration Agreement.
Amgen - Announced Research Collaboration Agreement to Discover & Create Protein Therapeutics for Five Clinical Targets.
Amgen - Co Will Pay $50 Million in Upfront Funding for Initial Five Programs With Potential Transaction Value of $1.9 Billion Plus Future Royalties.
Amgen - Co Will Also Participate in a Future Financing Round for Generate.
Amgen - Additional Terms of Collaboration Were Not Disclosed.
Amgen - Co Will Have the Option to Nominate Up to Five Additional Programs, at Additional Cost.
Amgen - for Each Program, Amgen Will Pay Up to $370 Million in Future Milestones & Royalties Up to Low Double Digits.
Further Company Coverage: Amgno ((reuters.
Briefs@thomsonreuters.
Com;)).